{"groups":[{"description":"TBL12 is administered orally at a dose of 2 units (of 20 mL each) twice a day, in 4-week cycles, until disease progression or there is sign of disease progression.","id":"FG000","title":"Sea Cucumber Extract (TBL 12)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"patient choice or noncompliance"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"20"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"15"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"From March 2011 to October 2012, 20 patients were enrolled to the study from Perlmutter Cancer Center at NYU Lagone Medical Center."}